Somatostatin receptor expression in Hürthle cell cancer of the thyroid.
Somatostatin receptor expression, which was not a previously described marker for Hürthle cell cancer of the thyroid, was demonstrated by in vivo imaging with (111)In-pentetreotide in three patients. This phenomenon not only adds another imaging technique to the nuclear medicine armamentarium for detecting recurrent and metastatic cancer in patients with Hürthle cell cancer but also opens up an alternative therapeutic avenue with somatostatin analogs or their radiolabeled compounds.
Gulec
S A
SA
Division of Nuclear Medicine, University of Miami School of Medicine Department, Florida, USA.
Serafini
A N
AN
Sridhar
K S
KS
Peker
K R
KR
Gupta
A
A
Goodwin
W J
WJ
Sfakianakis
G N
GN
Moffat
F L
FL
D018249:Adenoma, Oxyphilic / Q000000981:diagnostic imaging / Q000378:metabolism*; D000368:Aged; D006801:Humans; D007205:Indium Radioisotopes; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000031:analogs & derivatives; D004369:Pentetic Acid / Q000031:analogs & derivatives; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin / Q000032:analysis*; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism*
D007205:Indium Radioisotopes; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; C071632:SDZ 215-811; D004369:Pentetic Acid; D015282:Octreotide